Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. Khiron Life Sciences Corp.
  6. News
  7. Summary
    KHRN   CA49374L3065

KHIRON LIFE SCIENCES CORP.

(KHRN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Khiron Life Sciences : Renews Normal Course Issuer Bid

09/13/2021 | 04:21pm EDT


ę MT Newswires 2021
All news about KHIRON LIFE SCIENCES CORP.
10/07KHIRON LIFE SCIENCES : Medical Cannabis Company Khiron Life Sciences Outlines Results of F..
MT
10/07KHIRON LIFE SCIENCES CORP. : Invitation to the Benzinga Cannabis Capital Conference
NE
10/07Khiron Life Sciences Corp. Presents Its First Research Study with 1,400 Patients
CI
10/04KHIRON LIFE SCIENCES : to Present at Upcoming October Investor Conferences
AQ
10/04KHIRON LIFE SCIENCES : Details Operations Update as CFO Resigns
MT
10/01Khiron Life Sciences Corp. Announces Management Changes
CI
09/13KHIRON LIFE SCIENCES : Renews Normal Course Issuer Bid
MT
09/09KHIRON LIFE SCIENCES : Announces Intention to Renew Normal Course Issuer Bid
MT
09/09Khiron Life Sciences Corp. announces an Equity Buyback for 8,955,893 shares, representi..
CI
09/09Khiron Life Sciences Corp. authorizes a Buyback Plan.
CI
More news
Financials
Sales 2021 13,0 M 10,5 M 10,5 M
Net income 2021 -22,2 M -18,0 M -18,0 M
Net Debt 2021 15,0 M 12,2 M 12,2 M
P/E ratio 2021 -1,35x
Yield 2021 -
Capitalization 48,4 M 39,2 M 39,2 M
EV / Sales 2021 4,87x
EV / Sales 2022 2,16x
Nbr of Employees -
Free-Float 94,7%
Chart KHIRON LIFE SCIENCES CORP.
Duration : Period :
Khiron Life Sciences Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KHIRON LIFE SCIENCES CORP.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 0,27 CAD
Average target price 0,85 CAD
Spread / Average Target 215%
EPS Revisions
Managers and Directors
┴lvaro F. Torres Chief Executive Officer & Director
Swapan Kakumanu Chief Financial Officer
Chris Naprawa Chairman
Jairo Espinoza Vice President-Medical Affairs
Manuel Buendia Vice President-Operations
Sector and Competitors